Wat is de prijs voor Neumora Therapeutics, Inc. Common Stock (NMRA)

Het prijs van Neumora Therapeutics, Inc. Common Stock (NMRA) is $1.35

Wat is de marktkapitalisatie voor Neumora Therapeutics, Inc. Common Stock (NMRA)

Marktkapitalisatie voorNeumora Therapeutics, Inc. Common Stock (NMRA) is $249.21M

Neumora Therapeutics, Inc. Common Stock (NMRA) Prijs en Marktkapitalisatie

Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.

Prijs voor NMRA	Aandeel B	Marktkapitalisatie van B	uitslagen
$28,386.71 $249.21M	NVDA	$5.260T	+2,110,435.90%
$25,790.27 $249.21M	AAPL	$4.779T	+1,917,392.51%
$21,678.81 $249.21M	GOOG	$4.017T	+1,611,707.10%
$20,073.53 $249.21M	MSFT	$3.719T	+1,492,356.06%
$14,757.00 $249.21M	AMZN	$2.734T	+1,097,074.78%

Prijs voor NMRA

Aandeel B

Marktkapitalisatie van B

uitslagen

$28,386.71 $249.21M